Curis (CRIS) Net Cash Flow Growth (3y) (2013 - 2026)
Curis (CRIS) Net Cash Flow Growth (3y) (2013 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
NCF Growth (3y) (Qtr) |
| 1 |
Alterity Therapeutics |
788,338.31 Bn |
788,338.28 Bn |
- |
- |
| 2 |
Belite Bio |
56,560.00 Bn |
56,560.00 Bn |
- |
- |
| 3 |
Quantum Biopharma |
17,329.30 Bn |
17,329.30 Bn |
- |
- |
| 4 |
Legend Biotech |
3,341.00 Bn |
3,340.71 Bn |
242.10 Mn |
89.97% |
| 5 |
Akari Therapeutics |
1,727.91 Bn |
1,727.91 Bn |
- |
-13.44% |
| 6 |
Evaxion A |
1,536.68 Bn |
1,536.67 Bn |
- |
- |
| 7 |
Psyence Biomedical |
238.34 Bn |
238.33 Bn |
- |
- |
| 8 |
Vertex Pharmaceuticals |
113.42 Bn |
106.17 Bn |
2.59 Bn |
33.37% |
| 9 |
Abivax |
95.45 Bn |
95.45 Bn |
- |
- |
| 10 |
Curis |
8.58 Mn |
-6.42 Mn |
- |
-6.18% |
| Date | Value |
|---|
| Mar 31, 2026 |
-6.18% |
| Dec 31, 2025 |
26.85% |
| Sep 30, 2025 |
36.05% |
| Jun 30, 2025 |
-38.50% |
| Mar 31, 2025 |
26.27% |
| Dec 31, 2024 |
59.61% |
| Sep 30, 2024 |
35.57% |
| Jun 30, 2024 |
17.85% |
| Mar 31, 2024 |
29.59% |
| Dec 31, 2023 |
-72.47% |
| Sep 30, 2023 |
183.56% |
| Jun 30, 2023 |
-45.35% |
| Mar 31, 2023 |
83.25% |
| Dec 31, 2022 |
-25.87% |
| Sep 30, 2022 |
10.82% |
| Jun 30, 2022 |
44.12% |
| Mar 31, 2022 |
-46.22% |
| Dec 31, 2021 |
-89.05% |
| Sep 30, 2021 |
-65.17% |
| Jun 30, 2021 |
-102.34% |
